Colorectal cancer (CRC) represents approximately 10% of all cancers and is the second
most common cause of cancer deaths. Initial clinical presentation as metastatic CRC …

Over the past two decades, elucidation of the genetic defects that underlie cancer has
resulted in a plethora of novel targeted cancer drugs. Although these agents can initially be …

Abstract Background KRAS G12C is a mutation that occurs in approximately 3 to 4% of
patients with metastatic colorectal cancer. Monotherapy with KRAS G12C inhibitors has …

Abstract Background Divarasib (GDC-6036) is a covalent KRAS G12C inhibitor that was
designed to have high potency and selectivity. Methods In a phase 1 study, we evaluated …

Abstract Background KRAS p. G12C mutation occurs in approximately 1 to 2% of pancreatic
cancers. The safety and efficacy of sotorasib, a KRAS G12C inhibitor, in previously treated …

Background Adagrasib, an oral small-molecule inhibitor of mutant KRAS G12C protein, has
shown clinical activity in pretreated patients with several tumor types, including colorectal …

Despite being the most frequently altered oncogenic protein in solid tumours, KRAS has
historically been considered 'undruggable'owing to a lack of pharmacologically targetable …

PURPOSE Adagrasib, a KRASG12C inhibitor, has demonstrated clinical activity in patients
with KRAS G12C-mutated non–small-cell lung cancer (NSCLC) and colorectal cancer …

Covalent drugs have made a major impact on human health but until recently were shunned
by the pharmaceutical industry over concerns about the potential for toxicity. A resurgence …

After decades of efforts, we have recently made progress into targeting KRAS mutations in
several malignancies. Known as the 'holy grail'of targeted cancer therapies, KRAS is the …